Market recap

November 2024 in returns

November 2024 produced the single broadest advance in this entire record, and it was crypto that made it extraordinary. 79 of 80 coins finished green — 99% participation, a figure no other month approaches. Bitcoin rose 37.1%, Ethereum 47.0% and Solana 40.9%, but the majors were the modest part of it: Stellar gained 468.2%, Algorand 288.3%, XRP 282.9%, Hedera 267.3%, Cardano 215.7% and Sandbox 174.5%. Equities joined without hesitation — the Russell 2000 up 10.8%, the Dow 7.5%, the Nasdaq 6.2% — with 620 of 866 stocks (72%) higher and the VIX collapsing 41.7%.

The equity leaders were the same high-beta complex October had been accumulating, now paid off in full: Rocket Lab +154.9%, AppLovin +98.8%, Coinbase +65.2%, Palantir +61.4%, Robinhood +59.8%, MicroStrategy +58.5%. Almost nothing fell, and what did was defensive or foreign — Monolithic Power -25.2%, Bayer -21.8%, Moderna -20.8%. Whatever the trigger, the response was uniform rather than selective, which is what separates a repricing of risk appetite itself from a rotation between sectors. Months like this are exhilarating and rarely repeat; the hangover arrived immediately, and the coins that led here would spend most of 2025 giving it back.

Get next month’s recap by email

One email a month: the returns recap — what moved, and how unusual it was. No trading signals, no spam, unsubscribe in one click.

Not investment advice. See our privacy policy.

Headline moves

Breadth: 82 of 83 coins (99%) and 637 of 887 stocks/indices (72%) finished the month green.

Counts are the assets with a completed return for November 2024 — not the current universe. The crypto count moves month to month as coins enter and exit the top 600; new stock listings and delistings shift the equity count the same way.

Top crypto ▲ (over $5b)

Worst crypto ▼ (over $5b)

Top crypto ▲ (top 250)

Worst crypto ▼ (top 250)

Top stocks ▲

Worst stocks ▼

Biggest single large-cap move this month: RKLB (Rocket Lab Corporation) at +155%. This is a look back at the numbers, not financial advice — see our Terms.